menu
    • menu
    [{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Sinopharm Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Series B Financing","leadProduct":"GFH018","moa":"TGF-beta receptor 1","graph1":"Oncology","graph2":"Phase I","graph3":"GenFleet Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Sinopharm Capital","highestDevelopmentStatusID":"6","companyTruncated":"GenFleet Therapeutics \/ Sinopharm Capital"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"GFH925","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0.31,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.31,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Innovent Biologics"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Sellas Life Sciences Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"GFH009","moa":"CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GenFleet Therapeutics \/ SELLAS","highestDevelopmentStatusID":"6","companyTruncated":"GenFleet Therapeutics \/ SELLAS"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"BioLineRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2022","type":"Collaboration","leadProduct":"Motixafortide","moa":"CXCR4 ant","graph1":"Oncology","graph2":"Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GenFleet Therapeutics \/ GenFleet Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"GenFleet Therapeutics \/ GenFleet Therapeutics"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"GFH018","moa":"TGF beta-1","graph1":"Oncology","graph2":"Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GenFleet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GenFleet Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"GFH312","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GenFleet Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Merck","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Merck"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Sellas Life Sciences Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"GFH009","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GenFleet Therapeutics \/ GenFleet Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"GenFleet Therapeutics \/ GenFleet Therapeutics"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Verastem Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"GenFleet Therapeutics","amount2":0.64000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.64000000000000001,"dosageForm":"","sponsorNew":"GenFleet Therapeutics \/ GenFleet Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"GenFleet Therapeutics \/ GenFleet Therapeutics"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"GFH009","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GenFleet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Verastem Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"VS-7375","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"GenFleet Therapeutics","amount2":0.63,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.63,"dosageForm":"","sponsorNew":"GenFleet Therapeutics \/ GenFleet Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"GenFleet Therapeutics \/ GenFleet Therapeutics"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"SLS009","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GenFleet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"IBI351","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GenFleet Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"IBI351","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GenFleet Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"VS-7375","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GenFleet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GenFleet Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Verastem Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"VS-7375","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GenFleet Therapeutics \/ GenFleet Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"GenFleet Therapeutics \/ GenFleet Therapeutics"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Fulzerasib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GenFleet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"GenFleet Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by GenFleet Therapeutics

    Menu

    GenFleet Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GenFleet Therapeutics

                            China arrow
                            CPhI India 2024
                            Not Confirmed

                            GenFleet Therapeutics

                            China arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fulzerasib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GenFleet Announces KRAS G12C Inhibitor Approval in China for Lung Cancer

                            Details : Dupert (fulzerasib) is a novel small molecule KRAS G12C inhibitor, which is indicated for the treatment of patients with advanced solid tumors with KRAS G12C mutations.

                            Brand Name : Dupert

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 23, 2024

                            Lead Product(s) : Fulzerasib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GenFleet Therapeutics

                            China arrow
                            CPhI India 2024
                            Not Confirmed

                            GenFleet Therapeutics

                            China arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VS-7375

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Verastem Oncology

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Verastem Doses First Patient with GFH375/VS-7375 in Phase 1/2 Trial in China

                            Details : The collaboration aims to support the advancement of the clinical development of VS-7375/GFH375 in china, which is being evaluated in the treatment of KRAS G12D-mutant solid tumors.

                            Brand Name : VS-7375

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 12, 2024

                            Lead Product(s) : VS-7375

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Verastem Oncology

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            GenFleet Therapeutics

                            China arrow
                            CPhI India 2024
                            Not Confirmed

                            GenFleet Therapeutics

                            China arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VS-7375

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GenFleet's GFH375 IND Approved in China for KRAS G12D Tumors

                            Details : KRAS G12D oral selective small molecule inhibitor, GFH375 (VS-7375), is being investigated in patients with KRASG12D mutations, specifically in brain.

                            Brand Name : GFH375

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 19, 2024

                            Lead Product(s) : VS-7375

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            GenFleet Therapeutics

                            China arrow
                            CPhI India 2024
                            Not Confirmed

                            GenFleet Therapeutics

                            China arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IBI351

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GenFleet Announces FDA Approval for GFH925 Monotherapy in Phase 3 Colorectal Cancer Study

                            Details : GFH925 (IBI351) is a novel small molecule KRAS G12C inhibitor, which is being evaluated for the treatment of patients with colorectal cancer with KRAS G12C mutations.

                            Brand Name : GFH925

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 19, 2024

                            Lead Product(s) : IBI351

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            GenFleet Therapeutics

                            China arrow
                            CPhI India 2024
                            Not Confirmed

                            GenFleet Therapeutics

                            China arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SLS009

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GenFleet Receives FDA Fast Track and Orphan Drug Designations for GFH009

                            Details : SLS009 (GFH009) is a selective CDK9 inhibitor showing anti-tumor activity, investigated for relapsed/refractory peripheral T-cell lymphomas and acute myeloid leukemia.

                            Brand Name : GFH009

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 11, 2024

                            Lead Product(s) : SLS009

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            GenFleet Therapeutics

                            China arrow
                            CPhI India 2024
                            Not Confirmed

                            GenFleet Therapeutics

                            China arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VS-7375

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Verastem Oncology

                            Deal Size : $625.5 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development...

                            Details : Under the collaboration, Verastem selects a potential best-in-class KRAS G12D oral selective small molecule inhibitor, GFH375/VS-7375, as the lead program for its discovery and development for therapeutics targeting KRAS mutations.

                            Brand Name : GFH375

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 18, 2023

                            Lead Product(s) : VS-7375

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Verastem Oncology

                            Deal Size : $625.5 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            GenFleet Therapeutics

                            China arrow
                            CPhI India 2024
                            Not Confirmed

                            GenFleet Therapeutics

                            China arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IBI351

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            China's First NDA for a KRAS G12C Inhibitor: NMPA Accepts New Drug Application for GFH925 and Grants GFH925 wi...

                            Details : GFH925 (IBI351) is a novel small molecule KRAS G12C inhibitor, which is being evaluated for the treatment of patients with advanced solid tumors with KRAS G12C mutations.

                            Brand Name : GFH925

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 24, 2023

                            Lead Product(s) : IBI351

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            GenFleet Therapeutics

                            China arrow
                            CPhI India 2024
                            Not Confirmed

                            GenFleet Therapeutics

                            China arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GFH009

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GenFleet Starts Phase Ib/II Trial of GFH009 (Highly Selective CDK9 Inhibitor) Treating Patients with Relapsed/...

                            Details : SLS009 (GFH009) is a small molecule, highly selective CDK9 inhibitor, demostrated anti-tumor activity in the study being investigated for the treatment of relapsed/refractory PTCL (peripheral T-cell lymphomas).

                            Brand Name : GFH009

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 10, 2023

                            Lead Product(s) : GFH009

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            GenFleet Therapeutics

                            China arrow
                            CPhI India 2024
                            Not Confirmed

                            GenFleet Therapeutics

                            China arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Verastem Oncology

                            Deal Size : $637.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Pro...

                            Details : The collaboration is designed to allow Verastem the flexibility of a milestone-based option to license up to three compounds. The licenses would give Verastem development and commercialization rights outside of China while GenFleet would retain rights in...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : $11.5 million

                            August 28, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Verastem Oncology

                            Deal Size : $637.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            GenFleet Therapeutics

                            China arrow
                            CPhI India 2024
                            Not Confirmed

                            GenFleet Therapeutics

                            China arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GFH009

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Sellas Life Sciences Group

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SELLAS Announces Positive Topline Data from GFH009 Phase 1 Dose-Escalation Trial in Acute Myeloid Leukemia Coh...

                            Details : GFH009 is a small molecule, highly selective CDK9 inhibitor, demostrated anti-tumor activity in the study being investigated for the treatment of acute myeloid leukemia (AML).

                            Brand Name : GFH009

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 04, 2023

                            Lead Product(s) : GFH009

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Sellas Life Sciences Group

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth